Human Continuum Appoints Dr. Omar Khalid Sial, Ph.D., as its Chief Scientific Officer to Spearhead the Development of Innovative Extracellular Vesicle Topical Formulations and Advanced Biologic Therapies

New York, N.Y., Jan. 22, 2026 (GLOBE NEWSWIRE) — Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced the appointment of Dr. Omar Khalid Sial, Ph.D. as its Chief...

Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products

New York, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) — Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has appointed a leading orthopedic physician scientist...